Story perspectives

Guggenheim Lifts Elevance Health Price Target to $460

By Drooid · Oct 21, 2026, 2:39 PM UTC · How we work

Summary

Story summary

Guggenheim raised its price target for Elevance Health to $460.00 on October 12, 2026.
Elevance Health will release its third-quarter 2026 results before the market opens on October 21, 2026.
Elevance stock traded at €386.65 on October 20, 2026, 0.89 % above the Xetra close of €383.25.
Analysts expect third-quarter revenue of $49.29 billion and earnings per share of $4.70.

History

Historical Context

Anthem's $54 billion 2015 offer to buy Cigna was blocked in February 2017 and abandoned, setting a precedent for sharp analyst moves. In 2026 Guggenheim, founded 1999, lifted Elevance Health’s price target to $460—a 15% premium over $400. Renamed from Anthem in 2022, Elevance posted Q3 2026 revenue of $49.29 billion, reflecting the merger’s lasting valuation impact.

1 of 2

Story summary

Guggenheim raised its price target for Elevance Health to $460.00 on October 12, 2026.
Elevance Health will release its third-quarter 2026 results before the market opens on October 21, 2026.
Elevance stock traded at €386.65 on October 20, 2026, 0.89 % above the Xetra close of €383.25.
Analysts expect third-quarter revenue of $49.29 billion and earnings per share of $4.70.

1 / 2